Investigational personalized cellular therapy tolerated well by patients with advanced mesothelioma, ovarian and pancreatic cancers
Monday, April 20, 2015 - 09:30
in Health & Medicine
Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers. The data adds to a growing body of research showing the promise of CAR T cell technology.